NYSE:APUS | Free Cash Flow | Apimeds Pharmaceuticals US, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2023-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$2.07M$9,394.00-$2.08M
2025-12-31-$3.82M$21,424.00-$3.84M
2025-03-31-$20,313.00
2024-12-31-$99,616.00
2024-03-31-$263,100.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$8.93M$57,333.00-$8.98M
2024-12-31-$733,526.00
2023-12-31-$627,790.00